Description: Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Home Page: www.amgen.com
AMGN Technical Analysis
One Amgen Center Drive
Thousand Oaks,
CA
91320-1799
United States
Phone:
805 447 1000
Officers
| Name | Title |
|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & Pres |
| Mr. Peter H. Griffith | Exec. VP & CFO |
| Mr. Esteban Santos | Exec. VP of Operations |
| Dr. David M. Reese M.D. | Exec. VP of R&D |
| Mr. Murdo Gordon | Exec. VP of Global Commercial Operations |
| Ms. Linda H. Louie | VP of Fin. & Chief Accounting Officer |
| Mr. Mike Zahigian | Sr. VP & Chief Information Officer |
| Mr. Arvind Sood | VP of Investor Relations |
| Mr. Jonathan P. Graham | Exec. VP, Gen. Counsel & Sec. |
| Ms. Nancy A. Grygiel | Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 14.9477 |
|---|---|
| Trailing PE: | 21.679 |
| Price-to-Book MRQ: | 39.6029 |
| Price-to-Sales TTM: | 5.4945 |
| IPO Date: | 1983-06-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 24200 |